Compare Cassava Sciences Inc (FLNA) vs Western Digital Corp (WDC) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

Western Digital (WDC) trades at $405.21, down 1.42% amid recent sector volatility. The stock shows strong fundamentals with a P/E of 14.61 and impressive profitability metrics including 71.97% net income margin and 131.02% ROE. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $3.56 surpassing the $3.31 estimate. Technical indicators show bearish momentum with the price near key support at $400, while RSI at 29.60 suggests potential oversold conditions.

Despite near-term competitive pressures from Toshiba's production expansion, WDC maintains strong analyst support with 72% buy ratings and a $647.58 consensus target. The company's dominant 40%+ market share in HDDs and AI-driven storage demand provide long-term growth catalysts, though investors should monitor pricing pressure risks in the evolving AI storage landscape.